Policies regarding use of medications for opioid use disorder in professional recovery programs: A scoping review.
Subst Abus. 2022. DOI: 10.1080/08897077.2021.2010161
White KM, Hill LG, Perez JC, Torrez SB, Zagorski CM, Loera LJ.
Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA
Addiction. 2021. DOI: 10.1111/add.15314
Hill LG, Loera LJ, Evoy KE, Torrez SB, Renfro ML, Zagorski CM, Perez JC, Jones SM, Reveles KR.
Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19
Am J Health Syst Pharm. 2021. DOI: 10.1093/ajhp/zxab003
Peckham AM, Ball J, Colvard MD, Dadiomov D, Hill LG, Nichols SD, Tallian K, Ventricelli DJ, Tran TH.
Development of a health communication campaign to promote the Texas prescription monitoring program
Health Mark Q. 2020. DOI: 10.1080/07359683.2020.1802967
Mackert M, Pounders K, Brown L, Kirtz S, Hughes Wagner J, Ring D, Hill LG, Wilcox G, Murthy D, Tierney W, Innerarity S, McGlone M, Holleran Steiker LK, DeSalvo K, Bernhardt J, Pretorius K.
Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas
J Am Pharm Assoc. 2020. DOI: 10.1016/j.japh.2019.09.007
Evoy KE, Groff L, Hill LG, Godinez W, Gandhi R, Reveles KR.
Isotonitazene as a contaminant of concern in the illegal opioid supply: A practical synthesis and cost perspective
Int J Drug Policy. 2020. DOI: 10.1016/j.drugpo.2020.102939
Zagorski CM, Myslinski JM, Hill LG.
Mobilizing pharmacists to address the opioid crisis, a joint opinion of the ambulatory care and adult medicine practice and research networks for the American College of Clinical Pharmacy
J Am Coll Clin Pharm. 2020. DOI: 10.1002/jac5.1331
Coon SA, Hill LG, Hutchison RW, Arnold LM, Jarrett JB, Ottney AR, Oung AB, Painter NA, Smith MA, Stranges PM, Tran TH, McFee Winans AR, Bratberg JP.
Reply to a letter regarding, “Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction”
J Am Pharm Assoc. 2020. DOI: 10.1016/j.japh.2020.02.019
Hill LG, Evoy KE, Reveles KR.
Report of the 2020 special committee on substance use and pharmacy education
Am J Pharm Educ. 2020. DOI: 10.5688/ajpe8421
Tran T, Ball J, Bratberg JP, DeSimone EM, Franko TS, Hill LG, Koh-Knox Sharp CP, Palombi L, Ventricelli D, Farrell D, Gandhi N, Moore T.
Type and extent of opioid-related education provided by U.S. college of pharmacy continuing education divisions
Am J Pharm Educ. 2020. DOI: 10.5688/ajpe8001
Renfro ML, Moczygemba LR, Baumgartner J, Baumgart G, Hill LG.
Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction
J Am Pharm Assoc. 2019. DOI: 10.1016/j.japh.2019.06.019
Hill LG, Evoy KE, Reveles KR.
State-level approaches to expanding pharmacists’ authority to dispense naloxone may affect accessibility
JAMA Intern Med. 2019. DOI: 10.1001/jamainternmed.2019.3653
Hill LG, Reveles KR, Evoy KE.
Naloxone accessibility without a prescriber encounter under standing orders at community pharmacy chains in Texas
JAMA. 2018. DOI: 10.1001/jama.2018.15892
Evoy KE, Hill LG, Groff L, Mazin L, Carlson CC, Reveles KR.